Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A
February 2003
Marjan Bouma, Bastiaan Nuijen, Martine T. Jansen, Gianni Sava, Fabrizio Picotti, Antonella Flaibani, Auke Bult and Jos H. Beijnen
Journal of Pharmaceutical and Biomedical Analysis Volume 31, Issue 2 , 26 February 2003, Pages 215-228
You can view the abstract online. A subscription is required to view the full text or it can be purchased online.
Abstract
Imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III) (NAMI-A) is a novel ruthenium complex with selective activity against metastases currently in Phase I clinical trials in the Netherlands. Pharmaceutical quality control of NAMI-A drug substance and lyophilized product warranted the development of an assay for determination and quantification of NAMI-A and degradation products. A high performance liquid chromatography (HPLC) method was developed, consisting of a C18 column with 0.50 mM sodium dodecylsulfate in 3% methanol at pH 2.5 (acidified using trifluoromethanesulfonic acid) as the mobile phase and UV-detection at 358 nm. The HPLC method was proven to be linear, accurate and precise. Stress testing showed that degradation products were separated from the parent compound. By combining results of nuclear magnetic resonance (NMR) and HPLC experiments, one degradation product was identified as the mono-hydroxy species of NAMI-A. HPLC analysis with off-line detection of the eluate with flameless atomic absorption spectrometry (F-AAS) showed that under most conditions, all ruthenium-containing compounds show a peak in the HPLC chromatogram and that all ruthenium applied to the column is recovered quantitatively. For completely degraded solutions of NAMI-A some ruthenium is retained on the column. Suitability of the HPLC method for the pharmaceutical quality control of NAMI-A lyophilized product was demonstrated.